Cryoport, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Cryoport, Inc. on April 7, 2011, covering events occurring on April 4, 2011. The filing discloses the appointment of a new senior executive officer and details the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to executive compensation:
- Base Salary: $225,000 annually for the new Chief Commercial Officer.
- Incentive Bonus: Targeted at 30% of the annual base salary.
- Stock Options: 150,000 shares at $1.50/share (time-based vesting) and 100,000 shares at $1.50/share (performance-based vesting).
Material Changes
The primary material change is the appointment of Mark Englehart as Chief Commercial Officer. Mr. Englehart brings over 30 years of experience in pharmaceutical and biotechnology marketing and sales, with prior leadership roles at Cogent Performance Management, Esoterix Clinical Trials Services, Reliance Clinical Research Services, and Quest Diagnostics Clinical Trials.
Outlook, Risks, and Unusual Items
Compensatory Arrangements and Vesting Conditions:
- Time-Based Vesting: The 150,000-share option grant vests over four years, beginning six months after continuous employment, in equal six-month installments.
- Performance-Based Vesting: The 100,000-share option grant fully vests only when the Company achieves six months of sustainable positive cash flow from operations.
- Change of Control: In the event of a "change of control," Mr. Englehart is entitled to a severance payment equal to six months of base salary, and all unvested stock options will immediately vest in full.
Key Facts for Investor Verification
- Verify the Company's current cash flow status to assess the likelihood of the performance-based stock option vesting.
- Review the specific definition of "change of control" in Mr. Englehart's stock option agreement to understand potential dilution or liability triggers.
- Confirm the total number of authorized shares and the impact of the 250,000 new option grants on existing shareholder equity.
- Assess the strategic fit of Mr. Englehart's commercialization background with Cryoport's current business model.